期刊
NATURE MEDICINE
卷 20, 期 10, 页码 1126-1129出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3702
关键词
-
资金
- US NIH NIAID Vaccine Research Center
Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 With modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV Challenge.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据